According to the Zhitong Finance App, Hanyu Pharmaceutical (300199.SZ) issued an announcement. The company recently received the “Drug Registration Certificate” approved and issued by the State Drug Administration. Teriparatide is a recombinant human parathyroid hormone (1-34) analog used to treat osteoporosis in postmenopausal women with a high risk of fractures. This product can significantly reduce the risk of vertebral and non-vertebral fractures in postmenopausal women. Currently, there are 4 pharmaceutical companies listed in China, including EliLilly Nederland B.V., all of which are biological products. The company's teriparatide (H) injection is the first preparation approved in China according to the chemical synthesis route.

According to the Zhitong Finance App, Hanyu Pharmaceutical (300199.SZ) issued an announcement. The company recently received the “Drug Registration Certificate” approved and issued by the State Drug Administration. Teriparatide is a recombinant human parathyroid hormone (1-34) analog used to treat osteoporosis in postmenopausal women with a high risk of fractures. This product can significantly reduce the risk of vertebral and non-vertebral fractures in postmenopausal women. Currently, there are 4 pharmaceutical companies listed in China, including EliLilly Nederland B.V., all of which are biological products. The company's teriparatide (H) injection is the first preparation approved in China according to the chemical synthesis route.